GSK 3050002

Drug Profile

GSK 3050002

Alternative Names: Anti-CCL20 monoclonal antibody; E 6071; GSK-3050002; KANAb-071

Latest Information Update: 13 Feb 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline; KAN Research Institute
  • Developer GlaxoSmithKline; Morphotek
  • Class Monoclonal antibodies
  • Mechanism of Action CC chemokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Psoriatic arthritis; Ulcerative colitis

Most Recent Events

  • 18 Jan 2016 GlaxoSmithKline plans a phase I trial for Psoriatic arthritis in Spain, Romania, Belgium and United Kingdom (NCT02671188)
  • 01 Jan 2016 Phase-I clinical trials in Psoriatic arthritis in United Kingdom (IV) after January 2016 (UKCRN 19901; NCT02671188)
  • 01 Jan 2015 GlaxoSmithKline completes a phase I trial in Ulcerative colitis (In volunteers) in United Kingdom (NCT01984047)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top